Dare Bioscience, Inc. (DARE) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.77. The rating moved from Overbought to Strong Oversold on August 15, 2026.

• Public ratingStrong Oversold (as of August 19, 2026)
• Last close$0.77
• Last changeMoved from Overbought to Strong Oversold on August 15, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Dare Bioscience, Inc. (DARE) is a small-cap, development-stage biotechnology company with exposure to clinical and regulatory outcomes and limited commercial revenue. The combination of ongoing cash burn, likely need for near-term financing, and low liquidity creates meaningful downside risk absent positive pipeline news or partnership/license announcements. Broader market’s mild risk-on tone may provide short-lived support for speculative names, but longer-term improvement depends on concrete clinical, regulatory or commercial catalysts.

Key factors

• Early-stage clinical/biotech profile with limited or no meaningful commercial revenue
• High likelihood of continued cash burn and need for external financing or dilution
• Small market capitalization and low liquidity increases volatility and downside risk
• Potential upside from pipeline readouts, partnerships or licensing deals if positive
• Macro tone modestly risk-on in the short term could provide transient support for microcaps

Risks

• Dilution risk from equity raises or financing facilities that reduce existing shareholder value
• Clinical trial failure, regulatory setbacks, or negative readouts that could sharply cut valuation
• Competitive pressures from better‑funded peers or alternative therapeutic approaches
• Limited analyst coverage and sparse social/market sentiment data which can amplify price moves
• Operational execution risk including manufacturing/partnering delays and regulatory complexity

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.